Skip to content
ANAVEX
ANAVEXANAVEX
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPIPELINEPressUncategorized

Anavex Announces Panel Discussion and Presentation at OneMedForum Conference

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor

Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results

Anavex to Present at Biotech Showcase 2015 in San Francisco

Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

Anavex Upgrades to OTCQX Marketplace

Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s

Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference

Anavex to Present at SeeThruEquity Investor Conference in New York City

Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease

1
23456789101112
…1314151617…
181920212223242526
27
ANAVEX

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top